The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Luxembourg, A. T.
Right arrow Articles by Cooper, N. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luxembourg, A. T.
Right arrow Articles by Cooper, N. R.

The Journal of Immunology, Vol 153, Issue 10 4448-4457, Copyright © 1994 by American Association of Immunologists

ARTICLES

Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV

AT Luxembourg and NR Cooper
Scripps Research Institute, La Jolla, CA 92037.

CD21 is the receptor for C3dg and EBV. Several reports have shown that these CD21 ligands, and certain anti-CD21 mAb, trigger B cell activation, particularly when combined with Ag receptor ligation. However, the characteristics, biologic functions, and importance of this CD21-signaling pathway are unknown. We have used a model we recently developed to study B cell activation induced by complex particulate Ag, such as immune complexes and viruses, to begin to examine these questions. In the current studies, we incubated purified small resting B cells with 100-nm latex beads bearing various combinations of CD21 ligands and mAbs to CD19, CD35, and the Ag receptor. CD21, CD19, and CD35 have all been implicated in modulating membrane IgM initiated signaling. Beads coated with mAb to the C3dg/EBV- binding portion of CD21, but not mAb to other portions of the CD21 molecule, triggered B cell homotypic aggregation. Beads coated with the same CD21 ligands, although inactive alone, synergized with anti-IgM mAb in greatly increasing (20- to 180-fold) mRNA levels of the c-fos nuclear proto-oncogene. Signaling via CD21 was tyrosine kinase dependent. Levels of c-myc mRNA were not altered by CD21 ligands. Anti- CD19 and anti-CD35 mAb did not augment signaling via membrane IgM as assessed by changes in c-fos mRNA levels. These findings indicate that CD21 ligands binding to the C3dg/EBV-binding site of CD21 markedly augment B cell activation initiated by Ag receptor ligation via a selective, c-fos-dependent signaling pathway.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
A. C. Jacobson, J. J. Weis, and J. H. Weis
Complement Receptors 1 and 2 Influence the Immune Environment in a B Cell Receptor-Independent Manner
J. Immunol., April 1, 2008; 180(7): 5057 - 5066.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. M. Giles, S. N. Tchepeleva, J. J. Kachinski, K. Ruff, B. P. Croker, L. Morel, and S. A. Boackle
Augmentation of NZB Autoimmune Phenotypes by the Sle1c Murine Lupus Susceptibility Interval
J. Immunol., April 1, 2007; 178(7): 4667 - 4675.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Lee, K. M. Haas, D. O. Gor, X. Ding, D. R. Karp, N. S. Greenspan, J. C. Poe, and T. F. Tedder
Complement Component C3d-Antigen Complexes Can Either Augment or Inhibit B Lymphocyte Activation and Humoral Immunity in Mice Depending on the Degree of CD21/CD19 Complex Engagement
J. Immunol., December 15, 2005; 175(12): 8011 - 8023.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
L. Chakravarty, M. D. Zabel, J. J. Weis, and J. H. Weis
Depletion of Lyn kinase from the BCR complex and inhibition of B cell activation by excess CD21 ligation
Int. Immunol., February 1, 2002; 14(2): 139 - 146.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. W. Hess, M. G. Schwendinger, E.-L. Eskelinen, K. Pfaller, M. Pavelka, M. P. Dierich, and W. M. Prodinger
Tracing uptake of C3dg-conjugated antigen into B cells via complement receptor type 2 (CR2, CD21)
Blood, April 15, 2000; 95(8): 2617 - 2623.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
K. A. Boyle, R. L. Pietropaolo, and T. Compton
Engagement of the Cellular Receptor for Glycoprotein B of Human Cytomegalovirus Activates the Interferon-Responsive Pathway
Mol. Cell. Biol., May 1, 1999; 19(5): 3607 - 3613.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. A. Boackle, M. A. Morris, V. M. Holers, and D. R. Karp
Complement Opsonization Is Required for Presentation of Immune Complexes by Resting Peripheral Blood B Cells
J. Immunol., December 15, 1998; 161(12): 6537 - 6543.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. M. Prodinger, M. G. Schwendinger, J. Schoch, M. Kochle, C. Larcher, and M. P. Dierich
Characterization of C3dg Binding to a Recess Formed Between Short Consensus Repeats 1 and 2 of Complement Receptor Type 2 (CR2; CD21)
J. Immunol., November 1, 1998; 161(9): 4604 - 4610.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. W. Makar, C. T. N. Pham, M. H. Dehoff, S. M. O'Connor, S. M. Jacobi, and V. M. Holers
An Intronic Silencer Regulates B Lymphocyte Cell- and Stage-Specific Expression of the Human Complement Receptor Type 2 (CR2, CD21) Gene
J. Immunol., February 1, 1998; 160(3): 1268 - 1278.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
N. Sugano, W. Chen, M. L. Roberts, and N. R. Cooper
Epstein-Barr  Virus Binding to CD21 Activates the Initial Viral Promoter via NF-kappa B Induction
J. Exp. Med., August 29, 1997; 186(5): 731 - 737.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1994 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1994 by The American Association of Immunologists, Inc. All rights reserved.